03.08.2015GGBa offers you simultaneous translation !You are hereNewsGGBa offers you simultaneous translation !
Find an actor
BioAlps World Visibitlity Package 201918.03.2019A yearly international programme for our affiliated companies to increase their visibility.
"Bristol-Myers Squibb to Acquire Celgene for About Billion""The combined company will have nine products with more than billion in annual sales"
Tolerys SATherapeutics & Diagnostics, Other
Tolerys SA is an early stage biotech company developing a novel anti-inflammatory immunotherapy named EFD BCG. This product is derived from BCG vaccine using a patented inactivation process.
Therapeutics & Diagnostics, Vaccines
Preclinical studies proved that EFD BCG relies on its unique capacity to induce regulatory T cells in several models of chronic inflammatory diseases and is associated with a favorable safety profile.
In parallel to preclinical R&D, Tolerys SA has developed EFD BCG's manufacturing process and is preparing a first-in-man clinical trial.